ESTRO meets Asia 2024 - Abstract Book

S369

RTT – Patient experience and quality of life

ESTRO meets Asia 2024

Keywords: Hodgkins Lymphoma, AYA, survivorship

References:

Flerlage JE, Metzger ML, Bhakta N. The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice?. Blood, The Journal of the American Society of Hematology. 2018 Jul 26;132(4):376-84

143

Proffered Paper

Report on late effects of definitive hybrid brachytherapy followed by IMRT (HyBIRT) of tongue cancer Jasmin Bin Jalil 1 , Gokula Kumar Appalanaido 1 , Muhamad Yusri Musa 1 , Ewe Seng Ch’ng 1 , Syadwa Abdul Shukor 2 , Siti Noor Fazliah Mohd Noor 1 , Ahmad Fakrurrozi bin Mohamad 1 , Keerthaanaa Yogabalan 1 , Nor Hafizah Ishak 3 , Mohd Zahri Abdul Aziz 1 , Mohd Asraf Md Nor 1 , Siti Hajariah Kamaruddin 1 1 Advanced Medical & Dental Institute (AMDI), Universiti Sains Malaysia, Penang, Malaysia. 2 Department of Radiation Oncology, National University Cancer Institute, Singapore, Singapore. 3 Pusat Perubatan USM Bertam (PPUSMB), Universiti Sains Malaysia, Penang, Malaysia

Purpose/Objective:

We are presenting the incidence of late effects of the organ preservation approach with Hybrid Brachytherapy followed by IMRT(HyBIRT)technique for the definitive treatment of oral tongue Squamous Cell Carcinoma (TSCC) in patients who are unfit or refuse surgery. The clinical outcome in terms of local control (LC) (95%),locoregional control (LRC), overal survival (OS) and progression free survival(PFS) have been presented in the ESTRO 2023 as proffered paper (1). This prospective trial was approved by Institutional Review Board (JEPeM Code : USM/JEPeM/21080564)

Material/Methods:

Patients who underwent HyBIRT technique were followed-up at a regular interval of once a month for initial 6 months followed-by 3 monthly for a year and 6 monthly thereafter. Clinical assessment of the toxicity consisting of mucositis ,xerostomia , odynophagia, dysphagia , osteoradionecrosis, dysarthria , dysgeusia were recorded based on the common toxicity criteria version 5.0 (CTCAE 5.0) scoring.

Results:

33 TSCC patients underwent HyBIRT technique from December 2019 to December 2023, median follow-up is 24 months (range 8-48 months). All patients received 4 Gy x 5 twice-daily fractions of HDR-IBT followed by 69.96 Gy in 33 fractions of IMRT within 10 days after completing the HDR-IBT. All but 1 patient received concurrent chemotherapy. Patient and disease characteristics are as in table 1. 70% of patients are locally advanced (T3 & T4) and 88 % are nodal positive.

Table 1: Patient and disease characteristics

Patient characteristics

(n/%)

Median age (range)

54 (20-71) years